288 results on '"Orntoft, Torben F."'
Search Results
2. Prognostic Impact of a 12-gene Progression Score in Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study
3. An Optimized Shotgun Strategy for the Rapid Generation of Comprehensive Human Proteomes
4. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study
5. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy
6. Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma
7. SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism
8. Supplementary Table 2 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
9. Supplementary Figure 3 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
10. Data from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci
11. Supplementary Figure 2 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
12. Supplementary Figure 4 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
13. Supplementary Table 1 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
14. Supplementary Figure Legends from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
15. Supplementary Figure 1 from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci
16. Supplementary Tables 1-8 from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci
17. Supplementary Table 4 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
18. Supplementary Figure 5 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
19. Supplementary Figure 1 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
20. Supplementary Notes from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci
21. Supplementary Figure 3 from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci
22. Supplementary Table 3 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
23. Supplementary Figure 2 from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci
24. Supplementary Table from Identification of the Genes Up- and Down-Regulated by the High Mobility Group A1 (HMGA1) Proteins
25. Data from Identification of the Genes Up- and Down-Regulated by the High Mobility Group A1 (HMGA1) Proteins
26. The Application of MicroRNAs in Cancer Diagnostics
27. Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer
28. Mnk2 Alternative Splicing Modulates the p38-MAPK Pathway and Impacts Ras-Induced Transformation
29. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer
30. Combinations of Urinary Biomarkers for Surveillance of Patients with Incident Nonmuscle Invasive Bladder Cancer: The European FP7 UROMOL Project
31. Multicenter Validation of Cyclin D1, MCM7, TRIM29, and UBE2C as Prognostic Protein Markers in Non-Muscle–Invasive Bladder Cancer
32. Cathepsin E, Maspin, Plk1, and Survivin Are Promising Prognostic Protein Markers for Progression in Non-Muscle Invasive Bladder Cancer
33. High Expression of Karyopherin-α2 Defines Poor Prognosis in Non–Muscle-Invasive Bladder Cancer and in Patients with Invasive Bladder Cancer Undergoing Radical Cystectomy
34. STAT1 Is a Master Regulator of Pancreatic β-Cell Apoptosis and Islet Inflammation
35. Alternative Splicing of SLC39A14 in Colorectal Cancer is Regulated by the Wnt Pathway
36. Putative cis-regulatory drivers in colorectal cancer
37. Profiling of circulating microRNAs for prostate cancer biomarker discovery
38. Alternative Splicing in Colon, Bladder, and Prostate Cancer Identified by Exon Array Analysis
39. TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles
40. Isolation of Microarray-Grade Total RNA, MicroRNA, and DNA from a Single PAXgene Blood RNA Tube
41. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells
42. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH
43. Proteome profiling of corneal epithelium and identification of marker proteins for keratoconus, a pilot study.
44. Cytokines interleukin-1β and tumor necrosis factor-α regulate different transcriptional and alternative splicing networks in primary β-cells
45. Down-modulation of poly(ADP-ribose) polymerase-1 (PARP-1) in human TUR leukemia cells restores transcriptional responsiveness for differentiation and cell cycle arrest
46. Molecular Staging for Survival Prediction of Colorectal Cancer Patients
47. Preferential response of cancer cells to zebularine
48. Expression profiling confirms the role of endocytic receptor megalin in renal vitamin D3 metabolism
49. Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing
50. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington’s disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.